D R Newell - JoVE Visualize

Showing results (111-120 of 120) with videos related to

Pageof 12

Sort By:

You have reached the last page of results.This site can display upto 120 results.

Bioorganic & Medicinal Chemistry Letters|March 31, 2000

Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP)H C Barlow, K J Bowman, N J Curtin, et al.

British Journal of Cancer|June 13, 2014

Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastomaL Chen, Y Zhao, G C Halliday, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998

Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumorsI Rafi, A V Boddy, J A Calvete, et al.

Journal of Medicinal Chemistry|November 7, 2000

Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanineR J Griffin, C E Arris, C Bleasdale, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1982

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum IIA H Calvert, S J Harland, D R Newell, et al.

Investigational New Drugs|January 1, 1996

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acidS Laohavinij, S R Wedge, M J Lind, et al.

British Journal of Cancer|November 20, 1998

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanomaM R Middleton, J M Lunn, C Morris, et al.

British Journal of Cancer|January 5, 2001

A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group InvestigationE J Estlin, C R Pinkerton, I J Lewis, et al.

Journal of Medicinal Chemistry|August 24, 2000

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profilesC E Arris, F T Boyle, A H Calvert, et al.

British Journal of Cancer|September 23, 1998

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study GroupE J Estlin, L Lashford, S Ablett, et al.

Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:

Pageof 12

You have reached the last page of results.This site can display upto 120 results.

Bioorganic & Medicinal Chemistry Letters|March 31, 2000

Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP)H C Barlow, K J Bowman, N J Curtin, et al.

British Journal of Cancer|June 13, 2014

Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastomaL Chen, Y Zhao, G C Halliday, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998

Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumorsI Rafi, A V Boddy, J A Calvete, et al.

Journal of Medicinal Chemistry|November 7, 2000

Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanineR J Griffin, C E Arris, C Bleasdale, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1982

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum IIA H Calvert, S J Harland, D R Newell, et al.

Investigational New Drugs|January 1, 1996

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acidS Laohavinij, S R Wedge, M J Lind, et al.

British Journal of Cancer|November 20, 1998

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanomaM R Middleton, J M Lunn, C Morris, et al.

British Journal of Cancer|January 5, 2001

A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group InvestigationE J Estlin, C R Pinkerton, I J Lewis, et al.

Journal of Medicinal Chemistry|August 24, 2000

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profilesC E Arris, F T Boyle, A H Calvert, et al.

British Journal of Cancer|September 23, 1998

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study GroupE J Estlin, L Lashford, S Ablett, et al.

Pageof 12